UB Paderborn / Katalog / Suche / in CDI

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab

Annals of oncology, 2016-04, Vol.27 (4), p.732-738

2016

Link zum Volltext

Verfügbarkeit prüfen

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab

Annals of oncology, 2018-02, Vol.29 (2), p.524-524

2018

Link zum Volltext

Verfügbarkeit prüfen

Evidence for an association between Chlamydia psittaci and Ocular adnexal lymphomas

JNCI : Journal of the National Cancer Institute, 2004-04, Vol.96 (8), p.586-594

2004

Link zum Volltext

Verfügbarkeit prüfen

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

Annals of oncology, 2015-04, Vol.26 (4), p.798-803

2015

Link zum Volltext

Verfügbarkeit prüfen

ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy

ANNALS OF ONCOLOGY, 2019-10, Vol.30, p.v560-v561

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa

Annals of oncology, 2006-05, Vol.17 (5), p.769-772

2006

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

The New England journal of medicine, 2017-11, Vol.377 (19), p.1824-1835

2017

Link zum Volltext

Verfügbarkeit prüfen

Epigenetic remodelling of DNA in cancer

Histology and histopathology, 2007-12, Vol.22 (12), p.1413

2007

Link zum Volltext

Verfügbarkeit prüfen

Liver Metastases from Melanoma: Hepatic Intra-Arterial Chemotherapy. A Retrospective Study

Journal of chemotherapy (Florence), 2011-10, Vol.23 (5), p.300-305

2011

Link zum Volltext

Verfügbarkeit prüfen

469 Analyzing resistance of AXL- and/or MITF-expressing melanoma cells to immunotherapy

Journal of investigative dermatology, 2022-12, Vol.142 (12), p.S261-S261

2022

Link zum Volltext

Verfügbarkeit prüfen

1084MO Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial

Annals of oncology, 2023-10, Vol.34, p.S653-S654

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II study SECOMBIT (sequential combo immuno and target therapy study): A subgroup analysis with a longer follow-up

JOURNAL OF CLINICAL ONCOLOGY, 2022, Vol.40 (16_suppl), p.9535-9535

2022

Link zum Volltext

Verfügbarkeit prüfen

1083MO Brain metastases and survival evaluation in the SECOMBIT trial

Annals of oncology, 2023-10, Vol.34, p.S653-S653

2023

Link zum Volltext

Verfügbarkeit prüfen

49P A phase II randomized trial with adjuvant autologous tumor lysate-pulsed dendritic cells (DC) in resected stage III-IV melanoma patients: Preliminary immunological results

Annals of oncology, 2021-12, Vol.32, p.S1394

2021

Link zum Volltext

Verfügbarkeit prüfen

LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation

Annals of oncology, 2022-09, Vol.33, p.S1408-S1409

2022

Link zum Volltext

Verfügbarkeit prüfen

1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial

Annals of oncology, 2020-09, Vol.31, p.S734-S734

2020

Link zum Volltext

Verfügbarkeit prüfen

Regression of Ocular Adnexal Lymphoma After Chlamydia Psittaci–Eradicating Antibiotic Therapy

Journal of clinical oncology, 2005-08, Vol.23 (22), p.5067-5073

2005

Link zum Volltext

Verfügbarkeit prüfen

Dendritic cell vaccines manufacturing for treatment of cancer patients: a 11-year product quality control test collection of an advanced therapy medicinal product and compliance with the good manufacturing practices guideline

Cytotherapy (Oxford, England), 2021-05, Vol.23 (5), p.S168-S168

2021

Link zum Volltext

Verfügbarkeit prüfen

1074P Italian nivolumab Expanded Access Program (EAP) in melanoma adjuvant setting: Patients outcomes and safety profile

Annals of oncology, 2021-09, Vol.32, p.S890-S891

2021

Link zum Volltext

Verfügbarkeit prüfen

381TiP Vaccination with autologous dendritic cells loaded with autologous tumour homogenate in resected glioblastoma: A phase II study (CombiGVax)

Annals of oncology, 2021-09, Vol.32, p.S529-S529

2021

Link zum Volltext

Verfügbarkeit prüfen

Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus

Digestive and liver disease, 2007-09, Vol.39, p.S65-S71

2007

Link zum Volltext

Verfügbarkeit prüfen

1373TiP - ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy

Annals of oncology, 2019-10, Vol.30, p.v560-v561

2019

Link zum Volltext

Verfügbarkeit prüfen

ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy

JOURNAL OF CLINICAL ONCOLOGY, 2019, Vol.37 (15_suppl), p.TPS9599-TPS9599

2019

Link zum Volltext

Verfügbarkeit prüfen

LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)

Annals of oncology, 2020-09, Vol.31, p.S1173-S1174

2020

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab

Evidence for an association between Chlamydia psittaci and Ocular adnexal lymphomas

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy

Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Epigenetic remodelling of DNA in cancer

Liver Metastases from Melanoma: Hepatic Intra-Arterial Chemotherapy. A Retrospective Study

469 Analyzing resistance of AXL- and/or MITF-expressing melanoma cells to immunotherapy

1084MO Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial

Phase II study SECOMBIT (sequential combo immuno and target therapy study): A subgroup analysis with a longer follow-up

1083MO Brain metastases and survival evaluation in the SECOMBIT trial

49P A phase II randomized trial with adjuvant autologous tumor lysate-pulsed dendritic cells (DC) in resected stage III-IV melanoma patients: Preliminary immunological results

LBA41 Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation

1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial

Regression of Ocular Adnexal Lymphoma After Chlamydia Psittaci–Eradicating Antibiotic Therapy

Dendritic cell vaccines manufacturing for treatment of cancer patients: a 11-year product quality control test collection of an advanced therapy medicinal product and compliance with the good manufacturing practices guideline

1074P Italian nivolumab Expanded Access Program (EAP) in melanoma adjuvant setting: Patients outcomes and safety profile

LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study

381TiP Vaccination with autologous dendritic cells loaded with autologous tumour homogenate in resected glioblastoma: A phase II study (CombiGVax)

Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus

1373TiP - ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy

ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy

LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)

Suchergebnisse filtern